Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350877 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL95738 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2735604 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2352413 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2351564 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11753530 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL27965 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11032494 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11518271 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL8846723 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673432-A1 | SUGARCANE DERIVED SEMI-SYNTHETIC COSMETIC INGREDIENTS, METHODS OF PRODUCTION THEREOF, AND PERSONAL CARE PRODUCTS DERIVED THEREFROM | Amyris, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182684-A1 | SUGARCANE DERIVED SEMI-SYNTHETIC COSMETIC INGREDIENTS, METHODS OF PRODUCTION THEREOF, AND PERSONAL CARE PRODUCTS DERIVED THEREFROM | Amyris, Inc. (US) | 2024-09-06 | — | — | WO | claimed |
| CN-118435997-A | Method for regulating flavor components of fermented milk by using AI-2 | 内蒙古农业大学 | 2024-08-06 | — | — | CN | claimed |
| CN-117322510-A | Phagostimulant and feed based on fresh corn aroma substances as components and application of phagostimulant and feed | 合肥工业大学 | 2024-01-02 | — | — | CN | claimed |
| WO-2023172885-A1 | BRANCHED LIPID CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| CN-115715190-A | Redeciclovir and Redeciclovir analogs, solutions and nanoparticle, liposome and microparticle compositions for treating viral infections | 密歇根大学董事会 | 2023-02-24 | — | — | CN | claimed |
| EP-4110336-A1 | DIROFILARIA VOLATILE ORGANIC COMPOUND SIGNATURES AND USES THEREOF | Auburn University (US) | 2023-01-04 | — | — | EP | claimed |
| US-20220380290-A1 | ARYL TERPENE ESTERS | P2 SCIENCE, INC. | 2022-12-01 | — | — | US | claimed |
| WO-2022245835-A1 | ARYL TERPENE ESTERS | P2 SCIENCE, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20130052692-A1 | Host Cells and Methods for Producing 1-Deoxyxylulose 5-phosphate (DXP) and/or a DXP Derived Compound | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-28 | — | — | US | claimed |
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | claimed |
| EP-1828159-A1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSMIP Assets B.V. (NL) | 2007-09-05 | — | — | EP | claimed |
| WO-2006066863-A1 | ASYMMETRIC HYDROGENATION OF ALKENNES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS B.V. (NL) | 2006-06-29 | — | — | WO | claimed |
| US-20050191257-A1 | Dry deodorant containing a sesquiterpene alcohol and zinc oxide | COLGATE-PALMOLIVE COMPANY | 2005-09-01 | — | — | US | claimed |
| US-4039591-A | 1-ACETOXY-4-CHLORO-3-METHYLBUT-2-ENE | SCM CORPORATION (US) | 1977-08-02 | — | — | US | claimed |
| EP-4673432-A1 | SUGARCANE DERIVED SEMI-SYNTHETIC COSMETIC INGREDIENTS, METHODS OF PRODUCTION THEREOF, AND PERSONAL CARE PRODUCTS DERIVED THEREFROM | Amyris, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12365905-B2 | Host cells and methods for reducing isoprenoid precursors and isoprenoids by geranylgeranyl reductase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-22 | — | — | US | disclosed |
| US-4032647-A | HYPOLIPIDEMIC AGENTS | RICHARDSON-MERRELL INC. (US) | 1977-06-28 | — | — | US | disclosed |
| US-4000164-A | SUBSTITUTED FUROYLACETIC ACIDS AND ESTERS | RICHARDSON-MERRELL INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000169-A | ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191257-A1 | Dry deodorant containing a sesquiterpene alcohol and zinc oxide | FDFT1, SLC30A6, SLC30A7 | LMNA 3909/4885BLM 3235/4885PTPN1 4501/4885 |
| US-20220380290-A1 | ARYL TERPENE ESTERS | EBP, CYP4A11, LSS | LMNA 2885/4885BLM 2469/4885PTPN1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.